Various lots of cetirizine hydrochloride tablets have been recalled due to concerns over potential cross-contamination with ranitidine, a drug known to treat heartburn and related conditions. This announcement has prompted health officials to advise consumers, particularly those with a sensitivity to ranitidine, to exercise caution, as the contaminated medication could lead to severe allergic reactions.
:max_bytes(150000):strip_icc():format(jpeg)/Cetirizine-Hydrochloride-Tablets-USP-5-mg-RECALL-072226-1-7547f455ccc047f8855991eb020aa335.jpg)
The recall was issued by Unique Pharmaceutical Laboratories, a division of J. B. Chemicals & Pharmaceuticals Ltd. The affected products include four lots of 5-milligram cetirizine hydrochloride tablets that were distributed by Rising Pharma Holdings Inc. The U.S. Food and Drug Administration (FDA) reported the recall in a notice issued on July 20, indicating that Unique Pharmaceuticals had informed Rising Pharma, which in turn has communicated with its distributors and customers regarding the necessary return of the affected products.
Cetirizine, commonly recognized as a generic version of the popular allergy medication Zyrtec, is primarily used to alleviate symptoms associated with allergies. However, the potential for contamination with ranitidine presents a significant health risk. The FDA’s notice outlined the serious nature of this risk, stating that individuals who are hypersensitive to ranitidine may face life-threatening reactions if they ingest the contaminated tablets. Such reactions could manifest as anaphylaxis, characterised by symptoms such as a drop in blood pressure, difficulty breathing, swelling of the throat and face, widespread hives, and even loss of consciousness.
Despite the severity of the situation, Unique Pharmaceuticals has reported that it has not received any complaints or adverse events directly linked to the specific batches in question. The issue came to light following a report from a pharmacy technician, who noticed unusual red markings on some tablets while counting stock at the time of dispensing. Further investigation revealed additional discolouration on some of the tablets, prompting the decision for a recall.
The recalled cetirizine hydrochloride tablets were distributed in 100-count bottles to a number of wholesalers and retailers across the country. Those looking to identify affected products can check the label for specific details such as the product name, manufacturer, and lot numbers. The recalled bottles can be identified by a National Drug Code (NDC) of 16571-401-10, with an expiration date set for October 2028. The lot numbers impacted by the recall are GY825029, GY825030, GY825031, and GY825032.
Consumers who have questions regarding the recall, or who may need to report any adverse reactions associated with the tablets, can reach out to Rising Pharma Holdings Inc. during business hours. They can be contacted by phone at 1-844-874-7464 or via email at pv@risingpharma.com or qa@risingpharma.com. In addition, the FDA encourages individuals to report any adverse effects they may experience through its MedWatch Adverse Event Reporting Program, which can be accessed online, by mail, or via fax.
As a precaution, health officials recommend that consumers who believe they may have taken the affected tablets consult with their healthcare providers, particularly if they have experienced any troubling symptoms or reactions. The health and wellness of consumers remains a priority, and vigilance around medication safety is essential.
In light of this recall, awareness around product safety is more important than ever. Consumers should regularly check for updates regarding recalls, especially for over-the-counter medications that are widely used. Such incidents highlight the need for thorough monitoring and quality control within the pharmaceutical industry to safeguard public health.